Your browser doesn't support javascript.
loading
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.
Audrain, Mickael; Egesipe, Anne-Laure; Tentillier, Noémie; Font, Laure; Ratnam, Monisha; Mottier, Lorene; Clavel, Mathieu; Le Roux-Bourdieu, Morgan; Fenyi, Alexis; Ollier, Romain; Chevalier, Elodie; Guilhot, Florence; Fuchs, Aline; Piorkowska, Kasia; Carlyle, Becky; Arnold, Steven E; Berry, James D; Luthi-Carter, Ruth; Adolfsson, Oskar; Pfeifer, Andrea; Kosco-Vilbois, Marie; Seredenina, Tamara; Afroz, Tariq.
  • Audrain M; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Egesipe AL; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Tentillier N; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Font L; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Ratnam M; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Mottier L; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Clavel M; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Le Roux-Bourdieu M; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Fenyi A; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Ollier R; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Chevalier E; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Guilhot F; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Fuchs A; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Piorkowska K; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Carlyle B; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, UK.
  • Arnold SE; Department of Neurology and the Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
  • Berry JD; Sean M. Healey & AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Luthi-Carter R; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Adolfsson O; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Pfeifer A; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Kosco-Vilbois M; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Seredenina T; Research, AC Immune SA, 1015 Lausanne, Switzerland.
  • Afroz T; Research, AC Immune SA, 1015 Lausanne, Switzerland.
Brain Commun ; 5(6): fcad306, 2023.
Article en En | MEDLINE | ID: mdl-38025276
In amyotrophic lateral sclerosis, a disease driven by abnormal transactive response DNA-binding protein of 43 kDa aggregation, CSF may contain pathological species of transactive response DNA-binding protein of 43 kDa contributing to the propagation of pathology and neuronal toxicity. These species, released in part by degenerating neurons, would act as a template for the aggregation of physiological protein contributing to the spread of pathology in the brain and spinal cord. In this study, a robust seed amplification assay was established to assess the presence of seeding-competent transactive response DNA-binding protein of 43 kDa species in CSF of apparently sporadic amyotrophic lateral sclerosis patients. These samples resulted in a significant acceleration of substrate aggregation differentiating the kinetics from healthy controls. In parallel, a second assay was developed to determine the level of target engagement that would be necessary to neutralize such species in human CSF by a therapeutic monoclonal antibody targeting transactive response DNA-binding protein of 43 kDa. For this, evaluation of the pharmacokinetic/pharmacodynamic effect for the monoclonal antibody, ACI-5891.9, in vivo and in vitro confirmed that a CSF concentration of ≍1100 ng/mL would be sufficient for sustained target saturation. Using this concentration in the seed amplification assay, ACI-5891.9 was able to neutralize the transactive response DNA-binding protein of 43 kDa pathogenic seeds derived from amyotrophic lateral sclerosis patient CSF. This translational work adds to the evidence of transmission of transactive response DNA-binding protein of 43 kDa pathology via CSF that could contribute to the non-contiguous pattern of clinical manifestations observed in amyotrophic lateral sclerosis and demonstrates the ability of a therapeutic monoclonal antibody to neutralize the toxic, extracellular seeding-competent transactive response DNA-binding protein of 43 kDa species in the CSF of apparently sporadic amyotrophic lateral sclerosis patients.
Palabras clave